Annovis Bio, Inc. financial data

Symbol
ANVS on NYSE
Industry
Pharmaceutical Preparations
Location
101 Lindenwood Drive, Suite 225, Malvern, PA
State of incorporation
DE
Fiscal year end
December 31
Former names
QR Pharma, Inc. (to 3/15/2019)
Latest financial report
10-Q - Q3 2024 - Nov 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 345 % -57.8%
Debt-to-equity -746 % -3119%
Return On Equity 2.83K %
Return On Assets -438 % -148%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.8M shares +34.4%
Common Stock, Shares, Outstanding 13.3M shares +47.4%
Entity Public Float 91.5M USD +44.2%
Common Stock, Value, Issued 1.33K USD +47.2%
Weighted Average Number of Shares Outstanding, Basic 13M shares +44%
Weighted Average Number of Shares Outstanding, Diluted 13M shares +44%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 23.9M USD -33.8%
General and Administrative Expense 6.51M USD +3.32%
Operating Income (Loss) -30.4M USD +28.3%
Nonoperating Income (Expense) -10.5M USD -1659%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -40.9M USD +1.87%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -40.9M USD +1.87%
Earnings Per Share, Basic -3.85 USD/shares +20.3%
Earnings Per Share, Diluted -4.31 USD/shares +8.49%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 12.6M USD +98.8%
Assets, Current 7.81M USD -69.4%
Assets 14.4M USD +40.5%
Accounts Payable, Current 4.1M USD +113%
Employee-related Liabilities, Current 554K USD +39.7%
Liabilities, Current 5.39M USD +51.2%
Liabilities 7.3M USD +105%
Retained Earnings (Accumulated Deficit) -129M USD -46.5%
Stockholders' Equity Attributable to Parent 7.06M USD +6.09%
Liabilities and Equity 14.4M USD +40.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.03M USD +39.5%
Net Cash Provided by (Used in) Financing Activities 4.42M USD +59675%
Common Stock, Shares Authorized 70M shares 0%
Common Stock, Shares, Issued 13.3M shares +47.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.62M USD +77.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12.6M USD +98.8%
Deferred Tax Assets, Valuation Allowance 30.1M USD +63.1%
Deferred Tax Assets, Gross 30.1M USD +63.1%
Deferred Tax Assets, Operating Loss Carryforwards 9.61M USD +21.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2M shares 0%
Additional Paid in Capital 136M USD +43.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 393K USD -37.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%